Dr Lal PathLabs receives intimation of IT dept appeal before ITAT for AY 2022-23
- Dr. Lal PathLabs received intimation on October 7, 2026 of an Income Tax Department appeal filed before the Income Tax Appellate Tribunal, New Delhi
- The appeal challenges an appellate order for AY 2022-23 under section 250 of the Income Tax Act, 1961
- The dispute relates to disallowances of ESOP expenses of INR 32,66,18,927/- that the Commissioner of Income Tax (Appeals) had allowed as relief to the company
- The company does not reasonably expect the outcome of the appeal to have any material impact on its operations or finances
*this image is generated using AI for illustrative purposes only.
Dr. Lal PathLabs Limited received intimation on October 7, 2026 of an Income Tax Department appeal filed before the Income Tax Appellate Tribunal, New Delhi, against an appellate order for Assessment Year 2022-23.
Background of the tax dispute
The matter originates from an assessment order received by the company from the Income Tax Department, followed by an appellate order issued in favour of the company. The company had previously disclosed these developments through letters dated April 1, 2024 and July 17, 2026, respectively, in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
The Income Tax Department has now challenged the appellate order before the Income Tax Appellate Tribunal, New Delhi. The appeal was filed against the order of the Commissioner of Income Tax (Appeals), Income Tax Department, which had allowed relief to the company on disallowances of ESOP expenses.
Key details of the appeal
The following table summarises the material particulars of the intimation as disclosed by the company:
| Parameter | Details |
|---|---|
| Authority | Income Tax Appellate Tribunal, New Delhi |
| Nature of action | Income Tax appeal filed by the Income Tax Department against the Appellate Order for AY 2022-23 under section 250 of the Income Tax Act, 1961 |
| Date of receipt | October 7, 2026 (3:31 pm) |
| Amount in dispute | ESOP expense disallowances of INR 32,66,18,927/- |
| Expected financial impact | No material impact expected by the company |
Company's assessment of impact
Dr. Lal PathLabs has stated that it does not reasonably expect the outcome of the appeal to have any material impact on the company. The disclosure was made under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023.
Historical Stock Returns for Dr. Lal Path Labs
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -1.37% | -3.45% | +0.87% | +40.73% | +21.93% | +4.08% |
How might the Income Tax Appellate Tribunal's ruling on ESOP disallowances influence future tax compliance strategies for other Indian diagnostic companies?
Could a prolonged legal battle over the INR 32.66 crore dispute affect Dr. Lal PathLabs' investor sentiment or valuation multiples in the near term?
What are the potential implications for Dr. Lal PathLabs' capital allocation plans if the tribunal overturns the appellate order in favor of the tax department?
19
Access 50+ Readymade Screeners 
Use 200+ Custom Filters 
Get Full Market Insights 
